Calypso Biotech is a biotech company developing antibody therapies up to clinical proof-of-concept by leveraging its expertise in immunology and drug development. Calypso Biotech’s portfolio consists of two therapeutic antibody programs planned to reach the clinic by 2016-2017 against gastro-intestinal auto-immune syndromes such as Crohn’s and Refractory Celiac diseases.